Nonlinearity detection: Advantages of nonlinear mixed-effects modeling

AAPS PharmSci

Volumn 2, Issue 3, 2000, Pages 1-10

  Jonsson, E Niclas ^a,c   Karlsson, Mats O ^a   Wade, Janet R ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Nonlinear mixed effects modeling; Nonlinear pharmacokinetics and pharmacodynamics; Population analysis; Study design

Indexed keywords

EID: 33947234683     PISSN: 15221059     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ludden TM. Nonlinear pharmacokinetics. Clinical Implications. Clin Pharmacokinet. 1991;20:429-446.
2. Dutta S, Matsumoto Y, Ebling WF. Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies? J Pharm Sci. 1996;85:232-239.
3. Spigset O. The selective serotonin reuptake inhibitor fluvoxamine. Ume University medical dissertations, 1997.
4. Blackledge GRP. High-dose bicalutamide monotherapy for the treatment of prostrate cancer. Urology 1996:47(suppl 1A):44-47.
5. Sedman AJ, Wagner JG. Importance of the use of the appropriate pharmacokinetic model to analyse in vivo enzyme constants. J Pharmacokin Biopharm. 1974;2:161-173.
6. Sheiner LB, Rosenberg B, Marathe W. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokin Biopharm. 1977;5:445-479.
7. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters, ii. Biexponential model and experimental pharmacokinetic data. J Pharmacokin Biopharm. 1981;9:635-651.
8. Graves DA, Chang I. Application of NONMEM to routine bioavailability data. J Pharmacokin Biopharm. 1990;18:145-160.
9. Aarons O, Mandema JW, Danhof M. A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat. J Pharmacokin Biopharm. 1991;19:485-496.
10. Beal SL, Sheiner LB. NONMEM Users Guides. NONMEM Project Group, University of California at San Francisco, 1992.
11. Schoemaker RC, Cohen AF. Estimating impossible curves using NONMEM. B J Clin Pharmacol. 1996;42:283-290.
12. Hashimoto Y, Mori S, Hama N, Nakao K, Imura H, Yamaguchi M, Yasuhara M, Hori R. Nonlinear mixed effect modelling of the pharmacodynamics of natriuretic peptides in rats. J Pharmacokin Biopharm. 1993;21:281-297.
13. Hashimoto Y, Odani A, Tanigawara Y, Yasuhara M, Okuno T, and Hori R. Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. Biol Pharm Bull. 1994;17:323-326.
14. Hashimoto Y, Ozaki J, Koue T, Odani A, Yasuhara M, Hori R. Simulation for the analysis of distorted pharmacodynamic data. Pharm Res. 1994;11:545-548.
15. Beal SL, Sheiner LB. NONMEM Users Guide - Part VII. Conditional estimation methods. University of California at San Francisco, November 1992.
16. Rodman JH, Silverstein K. Comparison the two stage (TS) and first order (FO) methods for estimation of population parameters in an intensive pharmacokinetic study. Clin Pharmacol Ther. 1990;47:151.
17. Godfrey KR, Fitch WR. The deterministic identifiability of nonlinear pharmacokinetic models. J Pharmacokin Biopharm. 1984;12:177-191.
18. Godfrey KR, Fitch WR. On the identification of Michaelis-Menton elimination parameters from a single dose-response curve. J Pharmacokin Biopharm. 1984;12:193-221.
19. Godfrey KR, Chapman MJ, Vajda S. Identifiability and indistinguishability of nonlinear pharmacokinetic models. J Pharmacokin Biopharm. 1994;22:229-251.
20. Hashimoto Y, Koue T, Otsuki Y, Yasuhara M, Hori R, Inui K. Simulation for population analysis of Michaelis-Menton kinetics. J Pharmacokin Biopharm. 1995;23:205-216.